SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview, Jeong Woo Cho PhD, CEO & president of SK Biopharmaceuticals and SK Life Science, provides an overview of the current status of their drug development and commercialization efforts. Dr Cho also offers an insight into SK’s innovative AI platform, which can increase the efficiency of drug research and discovery and concludes with his assessment of the potential for the Korean pharmaceutical industry.
We need to conduct drug development in a smarter way utilizing bioinformatics and data mining tools
